Pages that link to "Q41833887"

The following pages link to Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid (Q41833887):

Displaying 22 items.

• Antibiotic treatment for Clostridium difficile -associated diarrhea in adults (Q24234378) (← links)
• Antibiotic treatment for Clostridium difficile-associated diarrhea in adults (Q24244302) (← links)
• Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance (Q26771995) (← links)
• Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults (Q30235446) (← links)
• A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection (Q30240264) (← links)
• New antimicrobial agents for patients with Clostridium difficile infections (Q34602195) (← links)
• Current and future treatment modalities for Clostridium difficile-associated disease (Q34767527) (← links)
• Antibiotics and resistance genes: influencing the microbial ecosystem in the gut. (Q36942502) (← links)
• The membrane as a target for controlling hypervirulent Clostridium difficile infections (Q36963920) (← links)
• Emerging therapies for Clostridium difficile infection - focus on fidaxomicin (Q36984883) (← links)
• Alternative therapies for Clostridium difficile infections (Q37813126) (← links)
• Emerging therapies forClostridium difficileinfections (Q37858531) (← links)
• Current state of Clostridium difficile treatment options (Q38023283) (← links)
• Therapy of Clostridium difficile infection: perspectives on a changing paradigm (Q38139991) (← links)
• Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571. (Q38719092) (← links)
• Therapies on the horizon for Clostridium difficile infections (Q38757930) (← links)
• CD2068 potentially mediates multidrug efflux in Clostridium difficile (Q41565399) (← links)
• MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile (Q42281252) (← links)
• Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile (Q42845938) (← links)
• Novel Antimicrobials for the Treatment of Clostridium difficile Infection. (Q55405974) (← links)
• Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postope (Q89814511) (← links)
• Calculated initial parenteral treatment of bacterial infections: Bacterial gastrointestinal infections (Q94563540) (← links)